ClinicalTrials.gg

Program

tizanidine

Also written as “Tizanidine”, “Zanaflex Capsules” and “tizanidine 8 mg”.

Its studies are mostly in Muscle Spasticity · Cognitive Dysfunction · Melanoma · Multiple Sclerosis · Cerebral Palsy, led by 4 companies.

Furthest: phase 3, since Jul 27, 20068 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industries30 open or runningphase 2since Jul 27, 2006Feb 2, 2006none ahead
Acorda Therapeutics20 open or runningphase 2since Apr 22, 2013Jul 25, 2011none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Feb 8, 2010Feb 8, 2010none ahead
Elan Pharmaceuticals10 open or runningphase 3since Oct 8, 2002Oct 8, 2002none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2002First study: phase 3 study in Multiple SclerosisNew to Elan PharmaceuticalsElan Pharmaceuticals · NCT00047580 · 120 enrolled · United States
  2. Feb 2, 2006Teva Pharmaceutical Industries's first study: phase 1 study in Brain Injuries, TraumaticNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00287157 · 5 enrolled · Israel
  3. Jul 27, 2006Phase 2 study in Muscle SpasticityTeva Pharmaceutical Industries · NCT00358293 · 20 enrolled · Israel
  4. Apr 22, 2007Phase 2 study in Muscle SpasticityTeva Pharmaceutical Industries · NCT00464958 · 10 enrolled · Israel
  5. Feb 8, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01065987, NCT01146028
  6. Jul 25, 2011Acorda Therapeutics's first study: phase 1 study in Spasticity Due to Cerebral PalsyNew to Acorda TherapeuticsAcorda Therapeutics · NCT01405950 · 10 enrolled · United States
  7. Apr 22, 2013Phase 2 study in Muscle SpasticityAcorda Therapeutics · NCT01839279 · 136 enrolled · United States

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brimonidineruleAbbViephase 454
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
Clonidinerulepharmafinaphase 45
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT01839279Muscle Spasticity · United States2CompletedAcorda TherapeuticsFeb 2014136
NCT01405950Spasticity Due to Cerebral Palsy · United States1TerminatedAcorda TherapeuticsMar 201210
NCT01146028Healthy · Canada1CompletedDr. Reddy's LaboratoriesSep 200142
NCT01065987Healthy · Canada1CompletedDr. Reddy's LaboratoriesSep 200124
NCT00464958Muscle Spasticity · Israel2TerminatedTeva Pharmaceutical IndustriesDec 200810
NCT00358293Muscle Spasticity · Israel2CompletedTeva Pharmaceutical Industries20
NCT00287157Brain Injuries, Traumatic · Israel1CompletedTeva Pharmaceutical Industries5
NCT00047580Multiple Sclerosis · United States3CompletedElan Pharmaceuticals120

How it is read

Names in the registry

  • “Tizanidine”, 4 entries
  • “Zanaflex Capsules”, 4 entries
  • “tizanidine 8 mg”, 1 entry
  • “tizanidine 8mg”, 1 entry
  • “tizanidine hydrochloride capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.